MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Life Sciences, Medical Devices & Health Information Technology
2025: Top 10 U.S. Biopharma Clusters 2025
Massachusetts
*Industry: Massachusetts
Aveo Pharmaceuticals (NASDAQ: AVEO)
Organization & Developments: Aveo
Parents
Aveo Pharmaceuticals (NASDAQ: AVEO)
Children
2011: Aveo Pharma Lands $1.4B Deal with Astellas, A Few Months Ahead of Cancer Trial Result(2011)
2014: Aveo outlines a path forward, but investors don't seem to be buying it
2014: Last remaining trial for Aveoâ™s lead cancer drug cancelled
2017: AVEO Pharmaceuticals (AVEO) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow - AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)
2018: AVEO Pharmaceuticals: An Update On This ~$3 Oncology Concern_seekingalpha.com
2018: AVEO Pharmaceuticals: TiNivo Results Impress, TIVO-3 Next - AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)
2018: Novartis dumps Aveo drug as relationship sours
2018: Our Current Take On This $3 Oncology Stock_seekingalpha.com
2019: Aveo Oncology stock plunges after delay in FDA approval submission for cancer drug
2019: AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why
2020: Aveo Oncology: Managing A Position Following Positive ASCO Data Readout
2020: AVEO Pharmaceuticals: Time For Redemption
2020: AVEO: Still A Speculative Buy Ahead Of FOTIVDA NDA Submission_seekingalpha.com
2021: AVEO Pharmaceuticals: Sticking To The Plan
2021: AVEO: Drug Approved, But Still A Long Way To Go Before Self Sufficiency
2022 AVEO Pharmaceuticals: Finally Ready To Reboot_seekingalpha.com
2022: AVEO Oncology: The Latest Acquisition Signals More Deals_seekingalpha.com
Cancer Treatment
Multitargeted kinase inhibitor, tivozanib, for the management of kidney cancer
The Aveo drug is an oral pill designed to very specifically block three different receptors of a protein called VEGF-which allows formation of new blood vessels that nourish tumors.
The deal helps a small company like Aveo with 150 employees to develop the drug for more types of tumors, building on the firm’s current work in kidney, breast, and colon cancers
Jumps
*Key People: Aveo
Finance & Acquisitions: Aveo